Validation of an LC‐Tandem MS/MS Method for the Determination of Etoricoxib in Human Plasma and Pharmaceutical Formulations

References

• Riendeau , D. , Percival , M. D. , Brideau , C. , Charleson , S. , Dubé , D. , Ethier , D. , Falgueyret , J.‐P. , Friesen , R. W. , Gordon , R. , Greig , G. , Guay , J. , Mancini , J. , Ouellet , M. , Wong , E. , Xu , L. , Boyce , S. , Visco , D. , Girard , Y. , Prasit , P. , Zamboni , R. , Rodger , I. W. , Gresser , M. , Ford‐Hutchinson , A. W. , Young , R. N. and Chan , C.‐C. 2001 . Etoricoxib (MK‐0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase‐2 . J. Pharmacol. Exp. Ther. , 296 ( 2 ) : 558 – 566 .
   PubMed Web of Science ®Google Scholar
• Rodrigues , A. D. , Halpin , R. A. , Geer , L. A. , Cui , D. , Woolf , E. J. , Matthews , C. Z. , Gottesdiener , K. M. , Larson , P. J. , Lasseter , K. C. and Agrawal , N. G.B. 2003 . Absorption, metabolism, and excrection of etoricoxib, a potent and selective cyclooxygenase‐2 inhibitor, in healthy male volunteers . Drug Metab. Dispos. , 31 ( 2 ) : 224 – 232 .
   PubMed Web of Science ®Google Scholar
• Agrawal , N. G.B. , Matthews , C. Z. , Mazenko , R. S. , Woolf , E. J. , Porras , A. G. , Chen , X. , Miller , N. , Michiels , M. , Wehling , A. , Schultz , A. , Gottlie , A. B. , Kraft , H. E. , Greenberg , S. A. , Waldman , S. P. , Curtis , S. P. and Gottesdiener , K. M. 2004 . The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of administration on CYP3A activity . J. Clin. Pharmacol. , 44 : 1125 – 1131 .
   PubMed Web of Science ®Google Scholar
• Agrawal , N. G.B. , Porras , A. G. , Matthews , C. Z. , Woolf , E. J. , Miller , J. L. , Mukhopadhyay , S. , Neu , D. C. and Gottesdiener , K. M. 2001 . Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase‐2 inhibitor, in healthy volunteers . J. Clin. Pharmacol. , 41 : 1106 – 1110 .
   PubMed Web of Science ®Google Scholar
• Agrawal , N. G.B. , Porras , A. G. , Matthews , C. Z. , Rose , M. J. , Woolf , E. J. , Musser , B. J. , Dynder , A. L. , Mazina , K. E. , Lasseter , K. C. , Hunt , T. L. , Schwartz , J. I. , McCrea , J. B. and Gottesdiener , K. M. 2003 . Single‐ and multiple‐dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase‐2, in man . J. Clin. Pharmacol. , 43 : 268 – 276 .
   PubMed Web of Science ®Google Scholar
• Dallob , A. , Hawkey , C. , Greenberg , H. , Wight , N. , De Schepper , P. , Waldman , S. , Wong , P. , Detora , L. , Gertz , B. , Agrawal , N. , Wagner , J. and Gottesdiener , K. 2003 . Characterization of etoricoxib, a novel, selective COX‐2 inhibitor . J. Clin. Pharmacol. , 43 : 573 – 585 .
   PubMed Web of Science ®Google Scholar
• Matthews , C. Z. , Woolf , E. J. , Lin , L. , Fang , W. , Hsieh , J. , Ha , S. , Simpson , R. and Matuszewski , B. K. 2001 . High‐throughput, semi‐automated determination of a cyclooxygenase II inhibitor in human plasma and urine using solid‐phase extraction in the 96‐well format and high‐performance liquid chromatography with post‐column photochemical derivatization‐fluorescence detection . J. Chromatogr. B , 751 : 237 – 246 .
   PubMed Web of Science ®Google Scholar
• Rose , M. J. , Agrawal , N. , Woolf , E. J. and Matuszewski , B. K. 2002 . Simultaneous determination of unlabeled and carbon‐13‐labeled etoricoxib, a new cyclooxygenase‐2 inhibitors, in human plasma using HPLC‐MS/MS . J. Pharm. Sci. , 91 ( 2 ) : 405 – 416 .
   PubMed Web of Science ®Google Scholar
• Bräutigam , L. , Nefflen , J. U. and Geisslinger , G. 2003 . Determination of etoricoxib in human plasma by liquid chromatography‐tandem mass spectrometry with electrospray ionisation . J. Chromatogr. B , 788 : 309 – 315 .
   PubMed Web of Science ®Google Scholar
• Werner , U. , Werner , D. , Hinz , B. , Lambrecht , C. and Brune , K. 2005 . A liquid chromatography‐mass spectrometry method for the quantification of both etoricoxib and valdecoxib in human plasma . Biomed. Chromatogr. , 19 : 113 – 118 .
   PubMed Web of Science ®Google Scholar
• Ramakrishna , N. V.S. , Vishwottam , K. N. , Wishu , S. and Koteshwara , M. 2005 . Validated liquid chromatographic ultraviolet method for the quantitation of etoricoxib in human plasma using liquid–liquid extraction . J. Chromatogr. B , 816 : 215 – 221 .
   PubMed Web of Science ®Google Scholar
• Lee , H. 2005 . Pharmaceutical applications of liquid chromatography coupled with mass spectrometry (LC/MS) . J. Liq. Chromatogr. & Rel. Technol. , 28 ( 7–8 ) : 1161 – 1202 .
   Web of Science ®Google Scholar
• Rao , R. N. , Meena , S. and Rao , A. R. 2005 . An overview of the recent developments in analytical methodologies for determination of COX‐2 inhibitors in bulk drugs, pharmaceuticals and biological matrices . J. Pharm. Biomed. Anal. , 39 : 349
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, Food and Drug Administration . 2001 . Guidance for Industry: Bioanalytical Method Validation Rockville, MD : Center for Drug Evaluation and Research .
   Google Scholar